Related Experiment Video

Updated: Jan 27, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

378

Agents to treat BRAF-mutant lung cancer

Jean G Bustamante Alvarez1, Gregory A Otterson1

  • 1Division of Medical Oncology, Department of Internal Medicine, The James Cancer Center and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.

Drugs in Context
|March 23, 2019
PubMed

Insights

BRAF mutations in non-small cell lung cancer (NSCLC) are linked to aggressive tumors. Targeted therapies like BRAF inhibitors offer better responses than chemotherapy, with immunotherapy emerging as a new option.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • BRAF mutations occur in 3.5-4% of non-small cell lung cancer (NSCLC) cases.
  • BRAF V600E mutations represent 50% of these alterations, with other non-V600E BRAF mutations comprising the remainder.
  • BRAF-mutated lung tumors often exhibit aggressive behavior and resistance to traditional chemotherapy.

Purpose of the Study:

  • To review the role of BRAF mutations in NSCLC.
  • To discuss the efficacy of targeted therapies and emerging treatment strategies for BRAF-mutated NSCLC.
  • To highlight advancements in treating this specific subset of lung cancer patients.

Main Methods:

  • Literature review of studies on BRAF mutations in NSCLC.
  • Analysis of treatment outcomes with tyrosine kinase inhibitors (TKIs), including BRAF and MEK inhibitors.
  • Evaluation of the role of immunotherapy in second-line treatment settings.

Main Results:

  • BRAF-mutated NSCLC shows increased aggressiveness and chemoresistance.
  • BRAF inhibitors, often combined with MEK inhibitors, demonstrate superior response rates compared to cytotoxic chemotherapy.
  • Immunotherapy is emerging as a viable treatment option for the second-line setting in BRAF-mutated NSCLC.

Conclusions:

  • Targeted therapies targeting BRAF mutations offer significant clinical benefit in NSCLC.
  • BRAF inhibitors and immunotherapy represent crucial advancements in managing BRAF-mutated NSCLC.
  • Personalized treatment approaches are essential for optimizing outcomes in NSCLC patients with specific genetic alterations.
Keywords:
dabrafenibimmunotherapylung neoplasmproto-oncogene protein B-raftrametinib

More Related Videos

Instillation and Fixation Methods Useful in Mouse Lung Cancer Research06:57

Instillation and Fixation Methods Useful in Mouse Lung Cancer Research

Published on: August 31, 2015

29.5K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.5K

Related Concept Videos

Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.2K
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
554
Air-entraining Agents01:27

Air-entraining Agents

Air-entraining agents improve the durability and workability of concrete in climates with frequent freezing and thawing. These agents prevent cracks by introducing small air bubbles into the mix, creating spaces accommodating water expansion when temperatures drop. The air-entraining agents lower the surface tension of water, forming stable, small air bubbles. This method is more effective than having accidental large voids, as the intentional, smaller, and evenly distributed air voids improve...
265
Masking and Demasking Agents01:19

Masking and Demasking Agents

EDTA titrations may necessitate masking and demasking agents to temporarily protect a particular metal ion in a mixture from the EDTA reaction. These agents facilitate the sequential analysis of the metal ions by forming stable complexes with some—but not all—metal ions during certain steps.
There are many masking agents, such as cyanide, fluoride, triethanolamine, thiourea, and 2,3-bis(sulfanyl)propan-1-ol (formerly 2,3-dimercapto-1-propanol), with the masking agent chosen based on...
3.5K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
621
Spasmolytic Agents: Chemical Classification01:29

Spasmolytic Agents: Chemical Classification

Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
1.3K